Drug Trial Radar · NCT06200597
A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
92
Actual
Start
Dec 5, 2023
Primary completion
May 11, 2025
Study completion May 29, 2025
Sponsor
- Lead sponsor
- Almirall, S.A.Industry
- Sponsor type
- Industry
- First posted
- Jan 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple ascending doses of LAD603 in healthy adult participants in both Part 1 and 2.
Conditions
- Healthy Volunteers
Interventions
LAD603Drug
LAD603 SC injection.
PlaceboOther
Matching placebo SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants with Adverse Events (AEs) and Severity of AEsTime frame: Baseline up to Day 31
- Part 1: Number of Participants with Clinically Significant Changes from Baseline in Vital Sign ParameterTime frame: Baseline up to Day 31
- Part 1: Number of Participants with Clinically Significant Changes from Baseline in Electrocardiograms (ECGs) ParametersTime frame: Baseline up to Day 31
- Part 1: Number of Participants with Clinically Significant Changes from Baseline in Clinical Laboratory ParametersTime frame: Baseline up to Day 31
- Part 2: Number of Participants with AEs and Severity of AEsTime frame: Baseline up to Day 64
- Part 2: Number of Participants with Clinically Significant Changes from Baseline in Vital Sign ParameterTime frame: Baseline up to Day 64
- Part 2: Number of Participants with Clinically Significant Changes from Baseline in ECGs ParametersTime frame: Baseline up to Day 64
- Part 2: Number of Participants with Clinically Significant Changes from Baseline in Clinical Laboratory ParametersTime frame: Baseline up to Day 64
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON Phase 1 unit Lenexa
Lenexa, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.